| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 141.59 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Vulvovaginal candidiasis is the second most common cause of vaginitis, affecting approximately 75% of women worldwide. It can be classified as either uncomplicated or complicated vulvovaginal candidiasis. The aim of the present study is to assess the knowledge of the Portuguese female population regarding genitourinary infections and the appropriate selection of medicines for their treatment. This observational study included 519 female participants, aged 18 years or older, residing in Portugal, who responded anonymously to an online questionnaire, between 26 March and 10 April, 2024. The scientific validity of the questionnaire was assessed using Cronbach’s alpha, with a sample of 30 participants. Data were analysed using SPSS software, specifically employing Fisher’s exact test and the Kruskal–Walli’s test. Results: It was found that 78.1% of participants identified fewer than half of the risk factors for vulvovaginal candidiasis, while 64.16% incorrectly considered a malodour to be a characteristic symptom. Additionally, 93.3% were aware of fewer than half of the available medicines for the treatment of uncomplicated vulvovaginal candidiasis. Furthermore, 71.6% and 83.6% of participants reported lacking the autonomy to self-medicate in cases of uncomplicated and complicated vulvovaginal candidiasis, respectively. A knowledge gap was identified among Portuguese women regarding vulvovaginal candidiasis and its pharmacological treatment. Educational level and age were found to significantly influence women’s knowledge of condition. The study highlights a deficiency in literacy regarding vaginal fungal infections within the Portuguese female community.
Descrição
Palavras-chave
Vulvovaginal candidiasis Women Antifungals
Contexto Educativo
Citação
Oliveira, T., Jesus, Â., Martins, J., & Moreira. (2025). The rational use of medicines in the treatment of vaginal fungal infections by the female population residing in Portugal. 13th APLF Annual Conference, TherapeuTic advances in drug safety 16(S1), 58–59. https://journals.sagepub.com/doi/epub/10.1177/20420986251379201
Editora
SAGE Publications
